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Abstract 
Bone marrow sampling remains essential in
the  evaluation  of  hematopoietic  and  many
non-hematopoietic  disorders.  One  common
limitation to these procedures is the discom-
fort  experienced  by  patients.  To  address
whether a Powered biopsy system could reduce
discomfort while providing equivalent or better
results,  we  performed  a  randomized  trial  in
adult  volunteers.  Twenty-six  subjects  under-
went bilateral biopsies with each device. Core
samples  were  obtained  in  66.7%  of  Manual
insertions;  100%  of  Powered  insertions
(P=0.002).  Initial  mean  biopsy  core  lengths
were  11.1±4.5  mm  for  the  Manual  device;
17.0±6.8  mm  for  the  Powered  device
(P<0.005).  Pathology  assessment  for  the
Manual  device  showed  a  mean  length  of
6.1±5.6 mm, width of 1.0±0.7 mm, and volume
of 11.0±10.8 mm3. Powered device measure-
ments  were  mean  length  of  15.3±6.1  mm,
width of 2.0±0.3 mm, and volume of 49.1±21.5
mm3 (P<0.001). The mean time to core ejec-
tion was 86 seconds for Manual device; 47 sec-
onds for the Powered device (P<0.001). The
mean second look overall pain score was 33.3
for the Manual device; 20.9 for the Powered
(P=0.039).  We  conclude  that  the  Powered
biopsy device produces superior sized speci-
mens, with less overall pain, in less time.
Introduction
Bone marrow evaluation is essential in the
diagnostic evaluation of both hematopoietic
and  many  non-hematopoietic  disorders,
determining the efficacy of treatment and to
monitor  the  recovery  process  in  patients
undergoing bone marrow transplantation or
marrow-ablative chemotherapy1,2 and is also
part  of  the  staging  process  for  newly  diag-
nosed patients with lymphoproliferative dis-
eases and certain non-hematopoietic malig-
nancies. Regardless of the diagnostic value of
the  biopsy  procedure,  the  pain  experienced
during and after the procedure makes some
patients fear the procedure and/or reluctant
to undergo follow-up biopsies. Attempting to
mitigate the procedural pain and discomfort,
some providers elect to use conscious seda-
tion during the bone marrow procedures; but
this  may  expose  the  patient  to  additional
physical  risks,  increased  liability  to  the
provider,  and  a  requirement  for  increased
patient monitoring during and after the pro-
cedure.3
Since 1971 the Jamshidi needle has been
the device of choice for bone marrow sam-
pling4 with  no  substantial  advancement  in
marrow  sampling  technology  thereafter.
Biopsy procedures facilitated by drill-powered
needles have been attempted, but with mixed
results.  In  1993,  Ahlstrom  and  Astrom
described  a  32-patient  study  in  which  a
makeshift bone biopsy system, that included a
power drill, was used to obtain the bone mar-
row  sample.  Successful  samples  were
obtained  in  43%  of  the  37  cases.5 More
recently, Buckley et al. describe a 68 patient
study in which patients underwent bone biop-
sy using a Black and Decker™ drill to access
the  iliac  crest.  Investigators  successfully
obtained  diagnostic  material  in  80%  of  the
cases with no major complications.6
OnControl is a battery-powered bone mar-
row  biopsy  system  (Vidacare  Corporation,
Shavano Park, TX, USA) which allows opera-
tors  to  quickly  and  efficiently  obtain  both
bone marrow core and aspirate (Figure 1). We
recently reported the preclinical comparison
of the OnControl to Manual biopsy in swine
together  with  an  uncontrolled  prospective
clinical evaluation for outpatient bone mar-
row  aspiration  and  biopsy.  These  findings
suggested that the Powered system was able
to  produce  specimens  of  equal  or  greater
quality faster and in a more efficient man-
ner.7 While prospective analysis has shown a
strong  correlation  between  the  duration  of
the procedure and the morbidity-particularly
with respect to patient discomfort,8 there has
not yet been a clinical study published com-
paring the new Powered device to traditional
Manual  bone  marrow  biopsy  needles.  We
report on this study designed to comparative-
ly determine if the Powered core biopsy nee-
dle  has  advantages  over  traditional  Manual
needles in terms of improved bone marrow
sample yield, decreased pain, and procedure
time.  
Materials and Methods 
This  single-center,  randomized,  controlled
trial was approved by IntegReview Institutional
Review Board, performed in accordance with the
Declaration of Helsinki and good clinical prac-
tice, and conducted in a community-based can-
cer clinic. After obtaining informed consent, a
medical history and demographics were record-
ed; followed by complete blood count analysis
(CBC) and a physical examination. Each sub-
ject,  serving  as  his/her  own  control,  received
bone marrow biopsy procedures using Powered
and Manual devices. The Powered device was
the  OnControl  Bone  Marrow  Biopsy  System
(Vidacare Corporation), an FDA-cleared device
consisting of a battery-powered driver and biop-
sy  needle  set.  The  driver  resembles  a  small
hand-held drill, and powers a single lumen nee-
dle set into the medullary cavity of the adult iliac
crest. The needle set consists of two parts: an
outer cannula, 11 gauge by 4 inches (102 mm)
long; and a bevel-tip inner stylet - used to pene-
trate the cortex. The Manual device used in the
study was a Jamshidi (Havel, Inc. Richmond,
VA) bone marrow biopsy needle (11 gauge by 4
inches), which has a two-piece T-handle design,
a trocar-tapered stylet point and a triple crown
cannula tip.
Two operators (one private practice and one
academic  hematologist/oncologist),  experi-
enced in the use of both devices, performed
the bone marrow procedures using the posteri-
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or iliac crest. The order in which the devices
were used on the subject, and which side was
biopsied first (right or left) was randomized.
Only one attempt was allowed for each device.
The  aspiration  component  of  standard  bone
marrow sampling was not performed for this
study. There was minimal time between the
two  biopsy  procedures;  just  enough  for  the
physicians to reposition after the first proce-
dure. Five to 7 mL of 1% Lidocaine buffered
with sodium bicarbonate was injected intra-
dermally, subcutaneously and periosteally as a
local anesthetic for each biopsy procedure. 
To assure that the subjects were not biased
towards  one  type  of  biopsy  needle  over  the
other, they were carefully screened and orient-
ed.  They were told that the purpose of the trial
was to see if there was a difference in the inten-
sity of pain experienced between the two types
of needles. They did not know, nor were they
told, if either of the needle types was preferred
by the investigators.  To minimize the noise
caused by the Powered device, and to decrease
the potential for the noise to compromise the
blinding of  procedure  order,  noise-cancelling
headphones were placed on the subjects during
each procedure. To further ensure that noise
was not a clue for the subject, a Powered device
was activated during the Manual procedure as
well. The time, in seconds, from contact of the
needle  with  skin  to  sample  acquisition  was
recorded.  Pain  was  measured  for  intensity
using a 100 mm Visual Analog Scale (VAS), with
scores ranging from 0 to 100, and higher scores
indicating  more  pain.  Participants  indicated
their pain level by placing a mark on a 100 mm
line at the instant of cortical penetration, biop-
sy  core  acquisition,  and  needle  removal.  An
overall procedure pain level was also recorded
immediately following each needle removal.  It
was recognized that since these volunteers had
never experienced bone marrow sampling pro-
cedures, the pain scores for the first procedure
might be skewed. Therefore, following the sec-
ond procedure, subjects were given the opportu-
nity to change the overall pain score indicated
for the first procedure. VAS pain scores were
also  recorded  30  minutes,  24  hours  and  48
hours after the procedure. Subjects were also
queried concerning complications at those time
points, with a final complication evaluation at 7
days post procedure. Immediately following the
procedures,  core  biopsy  samples  were  meas-
ured and submitted to a blinded pathologist for
quantitative and qualitative analysis. 
Statistical testing was conducted using SPSS
for Window 17.0 (SPSS, Inc. Chicago, IL, USA).
Continuous parameters were summarized and
compared between groups using a 2-sample t-
test. Categorical parameters were summarized
as  proportions  and  compared  using  Fisher’s
Exact test. Kaplan-Meier survival analysis com-
pared the bone marrow biopsy procedure time.
A priori significance level was set at 0.05.
Results
There were 26 subjects consented and ran-
domized into the study. One subject was dis-
qualified because the biopsy needle insertions
sites were not adequately anesthetized before
the start of procedures, and the subject did not
inform investigators of the inadequacy until
biopsy procedures were completed. The subject
subsequently experienced severe pain bilater-
ally  and  required  multiple  doses  of  narcotic
analgesia and repeated visits to medical facili-
ties for pain relief. Another subject was obese
and,  after  subcutaneous  insertion,  the  first
needle was not long enough to penetrate the
iliac crest cortex to complete the procedure.
The decision was made to not make a second
attempt and the subject was disqualified. Of
the  24  evaluable  subjects,  there  were  24
Manual insertions and 24 Powered insertions.
For those insertions, biopsy core samples were
obtained  in  66.7%  of  the  Manual  insertions
and 100% of Powered insertions - a significant
difference (P=0.002). The mean time to core
acquisition  was  85.7  seconds  for  Manual
device  and  46.5  seconds  for  the  Powered
device,  a  significant  difference  (P<0.001).
Using the second look overall pain score (for
those that opted to change their score), the
mean score for the Manual device was 33.3 and
20.9 for the Powered - a significant difference
(P=0.039). There was no statistical or clinical
difference in other pain scores between the
two  devices.  The  initial  mean  biopsy  core
length was 11.1±4.5 mm for the Manual device
and 17.0±6.8 mm for the Powered device; a
statistical difference (P<0.005). After fixation
and processing, pathology assessment for the
Manual  device  showed  a  mean  length  of
6.1±5.6mm, width of 1.0±0.7 mm, and volume
of  11.0±10.8  mm3.  Measurements  for  the
Powered device were mean length of 15.3±6.1
mm,  width  of  2.0±0.3  mm,  and  volume  of
49.1±21.5 mm3. All differences were statisti-
cally significant with P<0.001. For overall qual-
ity,  33.3%  of  Manual  samples  and  79.2%  of
Powered samples were graded adequate - a sta-
tistical difference (P=0.002). See Table 1.
Between operators, there was a difference
for mean time to core acquisition (75.5 sec-
onds vs 48.4 seconds, P=0.003), mean biopsy
core length (16.7 mm vs 12.0 mm, P=0.027),
and mean needle insertion VAS (19.4 vs 33.6,
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Table 1. Results by device. Results are compared with regard to device used for the procedure.
Variable Manual Powered P
(n=24) (n=24)
Successful core acquisition, first attempt (%) 66.7 100.0 0.002*
Mean time to core acquisition (seconds) 85.7±31.0 46.5±15.8 0.000*
Mean biopsy core length (mm) per acquired specimen 11.1±4.5 17.0±6.8 0.004*
Mean VAS needle insertion (0-100) 28.9±24.4 20.5±17.3 0.177
Mean VAS biopsy acquisition (0-100) 36.8±20.9 38.0±18.3 0.134
Mean VAS needle removal (0-100) 28.8±26.6 27.0±21.0 0.792
Mean VAS overall (0-100) 36.1±24.4 23.9±16.9 0.051
Mean VAS overall after 2ndlook adjustment (0-100) 33.3±23.9 20.9±15.6 0.039*
Mean VAS 30 minutes post procedure (0-100) 7.3±11.4 4.4±8.5 0.328
Mean VAS 24 hours post procedure (0-100) 5.8±8.5 9.1±13.8 0.325
Mean VAS 48 hours post procedure (0-100) 1.2±1.9 3.4±8.0 0.201
Pathology biopsy core length (mm) 6.1±5.6 15.3±6.1 <0.001*
Pathology biopsy core width (mm) 1.0±0.7 2.0±0.3 <0.001*
Pathology biopsy core volume (mm3) 11.0±10.8 49.1±21.5 <0.001*
Pathology-graded adequate biopsy core (%) 33.3 79.2 0.002*
*Denotes statistical significance; VAS, Visual Analog Scale.
Figure 1. The powered
bone  marrow  biopsy
system.  The  power
driver and biopsy nee-
dle components of the
OnControl  powered
bone  marrow  sam-
pling system.[page 24] [Hematology Reports 2011; 3:e8]
P=0.024).  Between  operators,  there  was  no
statistical difference in other VAS pain scores,
ability to capture a core specimen or propor-
tion of core biopsy specimens graded adequate
by pathology (See Table 2).
The  only  complication  noted  during  the
study was intense and extended pain experi-
enced  by  one  subject,  which  took  nearly  4
weeks to subside. 
Discussion
In  a  2009  article  describing  a  48-patient
study that assessed pain during biopsy proce-
dures,  Ruegg  and  associates  reported  mean
biopsy needle insertion pain to be 38.5 when
patients were anesthetized with buffered lido-
caine.3 In our study, in which buffered lido-
caine was also used, subjects rated their pain
at 38.0 on average with the Powered device.
When  given  the  opportunity  to  change  the
score for the first procedure, the mean pain
score for the Powered insertions was reduced
to 20.9.  
The procedure time (needle-to-skin contact
to core biopsy sample acquisition) was sub-
stantially  shorter  when  using  the  Powered
device.  Indeed,  in  Kuball’s  2004  publication
describing 263 patients undergoing bone mar-
row procedures, investigators reported that the
duration of the procedure, which averaged 7
minutes, was identified as the sole independ-
ent predictive factor for patients’ pain intensi-
ty.8 The investigators did not define how the
duration  of  needle  insertion  was  measured,
but the finding was quantitatively and qualita-
tively substantiated in our study. This was par-
ticularly true for patients with harder bones in
which more time and effort is required for cor-
tical  penetration.  In  our  study,  154  seconds
were  required  for  one  subject  using  the
Manual needle, compared to 70 seconds using
the  Powered  device.  For  this  subject,  the
Manual procedure resulted in a bent needle
(Figure 2) and no biopsy core sample.
While clinicians strive to conduct bone mar-
row  sampling  procedures  with  as  little  pain
and discomfort to the patient as possible, the
ultimate goal of the procedure is the acquisi-
tion of a specimen suitable for diagnosis by
pathologists.  Inadequate  specimens  have  a
significant impact on clinicians’ ability to treat
patients whose treatment depend an accurate
diagnosis. In a 767 patient study, Bishop et al.
reported that only 42% of their biopsy speci-
mens were adequate for accurate diagnosis.9
An adequate sample must be of sufficient size
and relatively free of crush artifact and trabec-
ular  distortion.  Greater  amounts  of  tissue
increase  the  chances  of  identifying  focal
lesions.  The superior core specimens acquired
using the Powered device is the key finding of
this study. Aside from a 100% first attempt core
capture rate compared to 67% for the Manual
device,  the  Powered  device  delivered  core
specimens  that  were  53%  longer,  and  con-
tained 346% more volume (Figure 3).
A  limitation  of  our  study  was  the  use  of
healthy volunteer subjects, rather than actual
patients. We found it would be difficult and
time-consuming for clinicians to accrue a sat-
isfactory number of patients requiring bi-later-
al procedures. A second reason is because pain
as a study outcome is generally problematic in
actual patients due to the great amount of vari-
ability, bias and subjectivity. These confound-
ing factors are multiplied with cancer patients
who often have underlying pain and an altered
perception of pain. Another limitation was the
decision not to collect a bone marrow aspirate
- a normal component of bone marrow sam-
pling procedures. For many patients, the nega-
tive pressure within the medullary space dur-
ing  the  syringe  aspiration  causes  the  worst
pain of the procedure, and the intensity of pain
is not a function of needle-type. For this rea-
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Table 2. Results by operator. Results are compared with regard to operator performing
the procedure.
Variable Operator A Operator B P
(n=30) (n=20)
Successful core acquisition, first attempt (%) 76.7 94.4 0.113
Mean time to core acquisition (seconds) 75.5±33.2 48.4±17.6 0.003*
Mean biopsy core length (mm) per acquired specimen 16.6±6.9 12.0±5.2 0.027*
Mean VAS needle insertion both needles (0-100) 19.4±17.4 33.6±24.7 0.024*
Mean VAS biopsy acquisition both needles (0-100) 28.6±18.9 38.7±20.6 0.090
Mean VAS needle removal both needles (0-100) 26.3±23.5 30.6±24.7 0.550
Mean VAS overall both needles (0-100) 24.8±20.1 34.0±22.5 0.327
Mean VAS overall after 2nd look adjustment both needles (0-100) 27.6±21.2 30.9±22.3 0.332
Mean VAS 30 minutes post procedure both needles (0-100) 5.3±9.9 6.8±10.6 0.607
Mean VAS 24 hours post procedure both needles (0-100) 9.0±12.8 5.0±8.9 0.247
Mean VAS 48 hours post procedure both needles (0-100) 2.6±7.2 1.8±2.6 0.641
Pathology biopsy core length (mm) 11.0±8.1 10.2±6.3 0.711
Pathology biopsy core width (mm) 1.4±0.8 1.7±0.6 0.187
Pathology biopsy core volume (mm3) 31.5±27.8 27.7±21.8 0.629
Pathology-graded adequate biopsy core (%) 60.0 50.0 0.104
*Denotes statistical significance; VAS, Visual Analog Scale.
Figure  2.  Manual  bone
marrow  biopsy  needle.
This shows the condition
of the manual needle fol-
lowing  insertion  into  a
patient with hard bones.
Figure  3.  Biopsy  core
specimens. These are typ-
ical  examples  of  bone
marrow  core  specimens
obtained following bilat-
eral bone marrow biopsy
procedures. Upper speci-
men  is  from  Manual
device  and  lower  speci-
men  is  from  Powered
device. [Hematology Reports 2011; 3:e8]
son, we opted to eliminate the aspiration com-
ponent. One other limitation was our failure to
standardize the amount of time between the
local anesthetic infiltration and the biopsy pro-
cedure. An additional limitation was failure to
capture total pain (e.g. intensity of the pain
times the duration of the pain). While the dif-
ference in the intensity of the pain did not
reach statistical significance in several of the
parameters tested, there is little doubt that the
duration of the pain was substantially longer in
the Manual arm of the study.  Several subjects
stated that they would much rather have the
Powered  needle  because  the  procedure  was
faster.
Conclusions
Results suggest the superior size and over-
all quality of core specimens delivered by the
Powered  device  provide  more  material  for
pathological evaluation of hematopoietic and
oncological disorders. The Powered device was
significantly faster in obtaining a biopsy than
the Manual device. The capture rate in obtain-
ing a satisfactory sample on first attempt was
much higher with the Powered device, negat-
ing the necessity of conducting a second biop-
sy.  While  the  Powered  bone  marrow  biopsy
showed a trend toward decreased pain overall
at  the  time  of  the  procedures,  use  of  the
Powered bone marrow biopsy device did signif-
icantly decreased overall procedure pain when
subjects considered the two procedures retro-
spectively.  
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